

Tianlei Ying

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6987586/publications.pdf>

Version: 2024-02-01

101
papers

5,294
citations

109321

35
h-index

95266

68
g-index

108
all docs

108
docs citations

108
times ranked

9536
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. <i>Emerging Microbes and Infections</i> , 2020, 9, 382-385.	6.5	1,086
2	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. <i>Cellular and Molecular Immunology</i> , 2020, 17, 765-767.	10.5	564
3	Identification of Human Single-Domain Antibodies against SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020, 27, 891-898.e5.	11.0	227
4	Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies. <i>Journal of Virology</i> , 2014, 88, 7796-7805.	3.4	212
5	Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1095-1097.	10.5	168
6	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 282.	17.1	149
7	Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. <i>Cell Reports</i> , 2020, 32, 107918.	6.4	148
8	A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. <i>Cellular and Molecular Immunology</i> , 2020, 17, 554-554.	10.5	124
9	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. <i>Cell Reports</i> , 2021, 34, 108699.	6.4	110
10	Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. <i>Nature Communications</i> , 2015, 6, 8223.	12.8	106
11	Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 212.	17.1	104
12	Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. <i>Virus Research</i> , 2014, 194, 200-210.	2.2	100
13	Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)â€™Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 1557-1561.	4.0	84
14	Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	84
15	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. <i>Cell</i> , 2022, 185, 1389-1401.e18.	28.9	82
16	Single-Domain Antibodies As Therapeutics against Human Viral Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 1802.	4.8	78
17	Ultrasensitive Detection of SARS-CoV-2 Antibody by Graphene Field-Effect Transistors. <i>Nano Letters</i> , 2021, 21, 7897-7904.	9.1	64
18	Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. <i>Biomaterials</i> , 2015, 41, 141-150.	11.4	58

#	ARTICLE	IF	CITATIONS
19	Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. <i>Emerging Microbes and Infections</i> , 2020, 9, 1988-1996.	6.5	58
20	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1591-1623.	12.0	57
21	Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns. <i>Journal of Advanced Research</i> , 2022, 37, 267-278.	9.5	57
22	Soluble Monomeric IgG1 Fc. <i>Journal of Biological Chemistry</i> , 2012, 287, 19399-19408.	3.4	53
23	Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains. <i>Journal of Virology</i> , 2014, 88, 1125-1139.	3.4	51
24	Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. <i>Scientific Reports</i> , 2016, 6, 31629.	3.3	50
25	Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 12904-12910.	13.8	49
26	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. <i>Cell Host and Microbe</i> , 2017, 22, 471-483.e5.	11.0	48
27	A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. <i>Cell Host and Microbe</i> , 2020, 28, 335-349.e6.	11.0	48
28	Ultraprecise Antigen 10-in-1 Pool Testing by Multiantibodies Transistor Assay. <i>Journal of the American Chemical Society</i> , 2021, 143, 19794-19801.	13.7	48
29	Fucoidan Extracted from the New Zealand <i>Undaria pinnatifida</i> – Physicochemical Comparison against Five Other Fucoidans: Unique Low Molecular Weight Fraction Bioactivity in Breast Cancer Cell Lines. <i>Marine Drugs</i> , 2018, 16, 461.	4.6	47
30	Engineered Soluble Monomeric IgG1 CH3 Domain. <i>Journal of Biological Chemistry</i> , 2013, 288, 25154-25164.	3.4	46
31	Development of Small-Molecule MERS-CoV Inhibitors. <i>Viruses</i> , 2018, 10, 721.	3.3	46
32	A Human DPP4-Knockin Mouse’s Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. <i>Viruses</i> , 2018, 10, 448.	3.3	42
33	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-11.	6.5	41
34	Development of therapeutics for treatment of Ebola virus infection. <i>Microbes and Infection</i> , 2015, 17, 109-117.	1.9	40
35	Immune Repertoire Diversity Correlated with Mortality in Avian Influenza A (H7N9) Virus Infected Patients. <i>Scientific Reports</i> , 2016, 6, 33843.	3.3	40
36	Human monoclonal antibodies as candidate therapeutics against emerging viruses. <i>Frontiers of Medicine</i> , 2017, 11, 462-470.	3.4	38

#	ARTICLE	IF	CITATIONS
37	Development of Small-Molecule Inhibitors Against Zika Virus Infection. <i>Frontiers in Microbiology</i> , 2019, 10, 2725.	3.5	38
38	Interactions of IgG1 CH2 and CH3 Domains with FcRn. <i>Frontiers in Immunology</i> , 2014, 5, 146.	4.8	33
39	Engineered Fc based antibody domains and fragments as novel scaffolds. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 1977-1982.	2.3	33
40	Discovery of T-Cell Infection and Apoptosis by Middle East Respiratory Syndrome Coronavirus. <i>Journal of Infectious Diseases</i> , 2016, 213, 877-879.	4.0	33
41	A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 539.	2.8	32
42	A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III. <i>PLoS Pathogens</i> , 2019, 15, e1007836.	4.7	32
43	Potent <i>In Vivo</i> NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. <i>Journal of Virology</i> , 2017, 91, .	3.4	31
44	Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. <i>Microbes and Infection</i> , 2015, 17, 142-148.	1.9	30
45	The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 132.	17.1	29
46	Deciphering Protein Corona by scFv-Based Affinity Chromatography. <i>Nano Letters</i> , 2021, 21, 2124-2131.	9.1	28
47	In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires. <i>Frontiers in Immunology</i> , 2018, 9, 128.	4.8	26
48	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 378.	17.1	26
49	Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. <i>MAbs</i> , 2015, 7, 922-930.	5.2	25
50	One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells. <i>Scientific Reports</i> , 2017, 7, 9130.	3.3	25
51	Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases. <i>MAbs</i> , 2014, 6, 1201-1210.	5.2	24
52	An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-12.	6.5	24
53	Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines. <i>Journal of Controlled Release</i> , 2021, 330, 493-501.	9.9	24
54	Preparation, Characterization, and Immuno-Enhancing Activity of Polysaccharides from <i>Glycyrrhiza uralensis</i> . <i>Biomolecules</i> , 2020, 10, 159.	4.0	22

#	ARTICLE	IF	CITATIONS
55	A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A. <i>Oncotarget</i> , 2017, 8, 81860-81872.	1.8	22
56	Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 657-671.	3.1	21
57	Arming Anti-EGFRvIII CAR-T With TGF β Trap Improves Antitumor Efficacy in Glioma Mouse Models. <i>Frontiers in Oncology</i> , 2020, 10, 1117.	2.8	19
58	A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. <i>Molecular Therapy</i> , 2022, 30, 2785-2799.	8.2	19
59	Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. <i>MAbs</i> , 2016, 8, 761-774.	5.2	17
60	Investigation of Different Molecular Weight Fucoidan Fractions Derived from New Zealand <i>Undaria pinnatifida</i> in Combination with GroA Therapy in Prostate Cancer Cell Lines. <i>Marine Drugs</i> , 2018, 16, 454.	4.6	15
61	From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1469-1478.	3.1	13
62	Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding. <i>Frontiers in Immunology</i> , 2017, 8, 1545.	4.8	13
63	Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants. <i>Virologica Sinica</i> , 2021, 36, 934-947.	3.0	12
64	New Directions for Half-Life Extension of Protein Therapeutics: The Rise of Antibody Fc Domains and Fragments. <i>Current Pharmaceutical Biotechnology</i> , 2016, 17, 1348-1352.	1.6	12
65	A Promising Intracellular Protein-Degradation Strategy: TRIMbody-Away Technique Based on Nanobody Fragment. <i>Biomolecules</i> , 2021, 11, 1512.	4.0	12
66	Facile Separation of PEGylated Liposomes Enabled by Anti-PEG scFv. <i>Nano Letters</i> , 2021, 21, 10107-10113.	9.1	12
67	Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). <i>Emerging Microbes and Infections</i> , 2015, 4, 1-2.	6.5	11
68	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. <i>Aids</i> , 2018, 32, 1749-1761.	2.2	11
69	Evaluation of antiviral - passive - active immunization (‘sandwich’) therapeutic strategy for functional cure of chronic hepatitis B in mice. <i>EBioMedicine</i> , 2019, 49, 247-257.	6.1	11
70	A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection. <i>MBio</i> , 2022, 13, .	4.1	10
71	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2019, 93, .	3.4	8
72	Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV. <i>Antibodies</i> , 2019, 8, 53.	2.5	8

#	ARTICLE	IF	CITATIONS
73	Recent Progress on Neutralizing Antibodies against Hepatitis B Virus and its Implications. <i>Infectious Disorders - Drug Targets</i> , 2019, 19, 213-223.	0.8	8
74	The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2022, 11, 1186-1190.	6.5	7
75	Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. <i>Scientific Reports</i> , 2017, 7, 6222.	3.3	6
76	Deep Mining of Human Antibody Repertoires: Concepts, Methodologies, and Applications. <i>Small Methods</i> , 2020, 4, 2000451.	8.6	5
77	Potential Nutraceutical Use of <i>Tribulus terrestris</i> L. in Human Health. <i>Food Reviews International</i> , 0, , 1-30.	8.4	5
78	Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection. <i>Molecules</i> , 2021, 26, 1964.	3.8	4
79	N-Butanol Subfraction of Brassica Rapa L. Promotes Reactive Oxygen Species Production and Induces Apoptosis of A549 Lung Adenocarcinoma Cells via Mitochondria-Dependent Pathway. <i>Molecules</i> , 2018, 23, 1687.	3.8	3
80	Recent advances in "universal" influenza virus antibodies: the rise of a hidden trimeric interface in hemagglutinin globular head. <i>Frontiers of Medicine</i> , 2020, 14, 149-159.	3.4	3
81	Decrease of Clone Diversity in IgM Repertoires of HBV Chronically Infected Individuals With High Level of Viral Replication. <i>Frontiers in Microbiology</i> , 2020, 11, 615669.	3.5	3
82	IgG-like Bispecific Antibody CD3 α -EpCAM Generated by Split Intein Against Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2022, 13, 803059.	3.5	3
83	An antigen-strengthened dye-modified fully-human-nanobody-based immunoprobe for second near infrared bioimaging of metastatic tumors. <i>Biomaterials</i> , 2022, 287, 121637.	11.4	3
84	Germlining of the HIV-1 broadly neutralizing antibody domain m36. <i>Antiviral Research</i> , 2015, 116, 62-66.	4.1	2
85	A systems approach to HIV-1 vaccines. <i>Nature Biotechnology</i> , 2016, 34, 44-46.	17.5	2
86	Precision immunomedicine. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-3.	6.5	2
87	Editorial: Antibody Fc Engineering: Towards Better Therapeutics. <i>Frontiers in Immunology</i> , 2018, 9, 2450.	4.8	2
88	Effects of preparation method on the biochemical characterization and cytotoxic activity of New Zealand surf clam extracts. <i>Heliyon</i> , 2020, 6, e04357.	3.2	2
89	Insights into biological therapeutic strategies for COVID-19. <i>Fundamental Research</i> , 2021, 1, 166-178.	3.3	2
90	Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. <i>Angewandte Chemie</i> , 2021, 133, 13014-13020.	2.0	2

#	ARTICLE	IF	CITATIONS
91	Functional reconstitution of the MERS CoV receptor binding motif. <i>Molecular Immunology</i> , 2022, 145, 3-16.	2.2	2
92	Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections. <i>Viruses</i> , 2022, 14, 1162.	3.3	2
93	No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5115-E5115.	7.1	1
94	Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0. <i>Methods in Molecular Biology</i> , 2018, 1827, 399-417.	0.9	1
95	A "sandwich"™ strategy promises functional cure of chronic hepatitis B. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 1-2.	0.7	1
96	Development of small-molecule inhibitors against hantaviruses. <i>Microbes and Infection</i> , 2020, 22, 272-277.	1.9	1
97	Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. <i>Small Methods</i> , 2022, 6, 2100966.	8.6	1
98	Characterization of human IgM and IgG repertoires in individuals with chronic HIV-1 infection. <i>Virologica Sinica</i> , 2022, 37, 370-379.	3.0	1
99	Counter changes with changelessness: cope with SARS-CoV-2 immune evasion by targeting cryptic epitopes. , 2022, 1, 24-26.		1
100	Establishment of Novel Monoclonal Fabs Specific for Epstein-Barr Virus Encoded Latent Membrane Protein 1. <i>Virologica Sinica</i> , 2019, 34, 467-470.	3.0	0
101	Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy. <i>Antibody Therapeutics</i> , 2021, 4, 89-98.	1.9	0